IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Liberty One Investment Management LLC

Liberty One Investment Management LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,143 shares of the medical research company’s stock after acquiring an additional 143 shares during the quarter. Liberty One Investment Management LLC’s holdings in IQVIA were worth $618,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of IQV. Nordea Investment Management AB lifted its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Versor Investments LP purchased a new stake in shares of IQVIA in the third quarter valued at about $1,328,000. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Finally, CIBC Asset Management Inc lifted its position in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IQV shares. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Redburn Atlantic started coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Robert W. Baird decreased their target price on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Morgan Stanley decreased their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Stock Down 0.2 %

IQV opened at $197.25 on Friday. The business’s fifty day simple moving average is $200.09 and its 200 day simple moving average is $221.29. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The firm has a market cap of $35.80 billion, a P/E ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.